Patrick Barry - Endo International President

President

Mr. PATRICK BARRY, is the Executive Vice President and Chief Commercial Officer of the company, effective February 26, 2018. In this role, he has responsibility for all commercial activities for U.S. Branded Pharmaceuticals, including strategy, new product planning, marketing, sales as well as managed care and patient access responsibilities since 2018.
Age 49
Tenure 6 years
Professional MarksMBA
Phone353 1 268 2000
Webhttps://www.endo.com
Barry joined Endo in December 2016 as Senior Vice President, U.S. Branded Pharmaceuticals. Prior to joining Endo, Mr. Barry worked at Sanofi S.A. from April 1992 until December 2016, holding roles of increasing responsibility in areas such as Sales Leadership, Commercial Operations, Marketing, Launch Planning and Training and Leadership Development. Most recently, he served at Sanofi S.A. as its General Manager and Head of North America General Medicines starting in September 2015 and as Vice President and Head of U.S. Specialty from April 2014 until August 2015. During this time, Mr. Barry oversaw three complex and diverse businesses with responsibility for leading sales and marketing activities for branded and generic products across the U.S. and Canada. He has a diverse therapeutic experience including aesthetics and dermatology, oncology, urology, orthopedics and medical device and surgical experience. He has an M.B.A. from Cornell University, Johnson School of Management and a B.A

Endo International Management Efficiency

The company has return on total asset (ROA) of 5.11 % which means that it generated a profit of $5.11 on every $100 spent on assets. This is normal as compared to the sector avarege. Endo International's management efficiency ratios could be used to measure how well Endo International manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 8.13 B in liabilities with Debt to Equity (D/E) ratio of 1.98, which is about average as compared to similar companies. Endo International PLC has a current ratio of 1.77, which is within standard range for the sector. Debt can assist Endo International until it has trouble settling it off, either with new capital or with free cash flow. So, Endo International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Endo International PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Endo to invest in growth at high rates of return. When we think about Endo International's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Greg WalkerBarrick Gold Corp
59
Billy SmithUS Silica Holdings
47
Lawrence SnappNational CineMedia
78
David MurryUS Silica Holdings
56
David Chung51Talk Online Education
N/A
Joseph DickEldorado Gold Corp
N/A
Kevin ThomsonBarrick Gold Corp
67
Ronald HoSandstorm Gold Ltd
N/A
Deni NicoskiBarrick Gold Corp
N/A
Thomas BruingtonSandstorm Gold Ltd
N/A
Scott FelensteinNational CineMedia
55
Jason ChoEldorado Gold Corp
N/A
Adam SpencerSandstorm Gold Ltd
N/A
Scott MelbyeUranium Energy Corp
62
Andor LipsEldorado Gold Corp
N/A
John BlanchardUS Silica Holdings
47
Ting Shu51Talk Online Education
38
Michael WinklerUS Silica Holdings
59
Timothy GarvinEldorado Gold Corp
N/A
David AwramSandstorm Gold Ltd
47
Philip YeeEldorado Gold Corp
N/A
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. Endo International operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NMS Exchange. It employs 3103 people. Endo International PLC (ENDP) is traded on NASDAQ Exchange in USA and employs 3,103 people.

Management Performance

Endo International PLC Leadership Team

Elected by the shareholders, the Endo International's board of directors comprises two types of representatives: Endo International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endo. The board's role is to monitor Endo International's management team and ensure that shareholders' interests are well served. Endo International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endo International's outside directors are responsible for providing unbiased perspectives on the board's policies.
Carrie Nichol, Chief Accounting Officer, Vice President Controller
William Spengler, Director
Arthur Higgins, Independent Director
Brian Lortie, President U.S. Branded Pharmaceuticals
Donald DeGolyer, Special Advisor to the CEO
William Montague, Director
Michael Hyatt, Director
Douglas Ingram, Director
Antonio Pera, President - Par Pharmaceutical
Domenic Ciarico, Executive Vice President Chief Commercial Officer - Sterile and Generics
Roger Kimmel, Chairman of the Board
Susan Hall, Chief Scientific Officer, Global Head of RandD and Quality and Executive VP
Sharad Mansukani, Director
Suketu Upadhyay, CFO and Executive VP
Nancy Hutson, Independent Director
Todd Sisitsky, Director
Patrick Barry, Executive Vice President and Chief Commercial Officer
Shane Cooke, Independent Director
Craig Paterson, Chief Medical Officer
Daniel Rudio, Senior Vice President Chief Accounting Officer, Controller
Camille Farhat, President of American Medical Systems, Inc
Paul Campanelli, President CEO, Director
Jill Smith, Director
Rajiv Silva, CEO and President and Director
Nina Goworek, Senior Director, Investor Relations
Blaise Coleman, Senior Vice President of Global Finance Operations and Interim CFO
Terrance Coughlin, COO, Executive Vice President
Matthew Maletta, Executive Vice President Chief Legal Officer

Endo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Endo International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Endo International in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Endo International's short interest history, or implied volatility extrapolated from Endo International options trading.

Pair Trading with Endo International

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Endo International position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endo International will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Endo International PLC information on this page should be used as a complementary analysis to other Endo International's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Consideration for investing in Endo Stock

If you are still planning to invest in Endo International PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Endo International's history and understand the potential risks before investing.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital